EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Infliximab abrogates adenine-induced chronic kidney disease via modulation of the MAPK/JNK/ASK signaling pathway in rats

Mahitab M Nageeb, Aliaa Talaat, Samar M Reda, Ghada A Elsammak

Naunyn-Schmiedeberg's Archives of Pharmacology · 2024

DOI: 10.1007/s00210-023-02585-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2024. Verfasst von Mahitab M Nageeb und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Zagazig University, Zagazig, Egypt. MMAbdulWahab@medicine.zu.edu.eg. Hauptthemen laut MEDLINE: Adenine, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zagazig University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) is a prominent cause of death worldwide. Infliximab is one of the anti-TNF-α; herein, we studied the effect of infliximab on adenine-induced CKD. To inspect the role of infliximab, either ameliorative or curative, on CDK induced with adenine. Thirty Wistar albino rats were separated into five groups of 6 rats’ each: rats of group Ι were kept as control given saline, rats of group II were treated with infliximab (5 mg/kg, i.p.) for 5 weeks, rats of group ΙΙΙ (the diseased group) had an adenine containing diet (0.25% W/W in feed) for 5 weeks, rats of group ΙV (the ameliorative group) had an adenine-containing diet and infliximab (5 mg/kg, i.p.) for 5 weeks simultaneously, and rats of group V (the curative group) had adenine containing diet then a single dose of infliximab (5 mg/kg, i.p.) was given in the 6th week. Infliximab treatment revealed a decrease in the plasma levels of urea, creatinine, NGAL, and MDA with a substantial increase in TAC. Also, inflammatory mediators such as IL-6 and NF-κB were significantly decreased with the down-regulation of the ASK1/MAPK/JNK pathway. Caspase 3 was downregulated. Also, infliximab treatment exhibited improvement in the histological and immunohistochemical kidney changes. Through its involvement in reducing oxidative stress, inflammation, and apoptosis, infliximab has an ameliorative and curative effect on CKD induced with adenine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenineRenal Insufficiency, ChronicRatsAnimalsInfliximabRats, WistarMAP Kinase Signaling SystemTumor Necrosis Factor InhibitorsKidneyOxidative Stress

Stichwörter der Autor:innen

AdenineApoptosisChronic kidney diseaseInflammationInfliximabOxidative stress

Substanzen

InfliximabAdenineTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Medicine, Zagazig University, Zagazig, Egypt. MMAbdulWahab@medicine.zu.edu.eg.
  • Department of Medical Biochemistry, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
  • Department of Histology and Cell Biology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.

Förderung

  • Zagazig University

Zitieren

APA

Nageeb, M. M., Talaat, A., Reda, S. M., & Elsammak, G. A. (2024). Infliximab abrogates adenine-induced chronic kidney disease via modulation of the MAPK/JNK/ASK signaling pathway in rats. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-023-02585-4

Vancouver

Nageeb MM, Talaat A, Reda SM, Elsammak GA. Infliximab abrogates adenine-induced chronic kidney disease via modulation of the MAPK/JNK/ASK signaling pathway in rats. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024. doi:10.1007/s00210-023-02585-4

BibTeX
@article{Nageeb2024,
  author = {Nageeb, Mahitab M and Talaat, Aliaa and Reda, Samar M and Elsammak, Ghada A},
  title = {Infliximab abrogates adenine-induced chronic kidney disease via modulation of the MAPK/JNK/ASK signaling pathway in rats},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2024},
  doi = {10.1007/s00210-023-02585-4}
}
Kostenlos starten →